New Analysis Suggests Pricey Gilead Sciences, Inc. (GILD) Drug Will Bust State Budgets
7/18/2014 7:49:36 AM
Will the cost of new hepatitis C treatments bust state budgets?
A new analysis suggests many states may, in fact, be overwhelmed as they attempt to pay for the Solvaldi medication sold by Gilead Sciences (GILD)which costs $84,000 for each patient, and several forthcoming treatments that may be priced at a similar level.
Help employers find you! Check out all the jobs and post your resume.
comments powered by